Cagrilintide is an investigational, once-weekly injectable analogue of amylin, a hormone the pancreas releases alongside insulin. Novo Nordisk is developing it both alone and, more famously, combined with semaglutide in a product called CagriSema. As a single drug it produced 11.8 percent weight loss over 68 weeks in its largest trial, a real but more modest number than the combination’s 22.7 percent, and the two figures are frequently mixed up online. It is not approved anywhere yet; a US filing for the combination was submitted in December 2025.
Ask about Cagrilintide / CagriSema
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Amylin analogue, dual amylin/calcitonin receptor agonist, synthetic peptide (investigational) |
| Primary research interest | Weight management (standalone and combined with semaglutide as CagriSema), type 2 diabetes glycemic control |
| Highest available evidence | Tier 1: multiple published human phase 2/3 trials (Lancet, NEJM), including REDEFINE 1 and 2 |
| Human research available | Yes: large phase 2/3 programme (REDEFINE, REIMAGINE, RENEW) |
| Development status | In clinical development; US filing for the CagriSema combination submitted December 2025, not yet approved |
| Regulatory status | Not approved anywhere in the world, alone or combined |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Cagrilintide |
| Alternative names | AM833, NNC0174-0833 |
| Peptide sequence | {eicosanedioic acid-gamma-Glu}-KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2; six substitutions against human amylin (N14E, V17R, A25P, S28P, S29P, Y37P) |
| Amino-acid length | 37 |
| Molecular formula | C194H312N54O59S2 (supplier data sheet only, not confirmed against a peer-reviewed or regulatory source) |
| Molecular weight | ≈4,409.01 g/mol (supplier-derived, not independently confirmed) |
| CAS Registry Number | 1415456-99-3 (supplier-derived and cross-listed on secondary references, not confirmed against a primary source) |
| PubChem CID | 167312356 |
| Chemical modifications | C20 dicarboxylic acid (eicosanedioic acid) on Lys1 via gamma-glutamate linker, for albumin binding; native Cys2-Cys7 disulfide retained; half-life about 6.6 to 8.1 days |
| Peptide class | Dual amylin and calcitonin receptor agonist |
| Primary biological target | Amylin/calcitonin receptor heterodimers (AMY1, AMY2, AMY3) in the hindbrain |
| Developer / originator | Novo Nordisk |
| Development status | Investigational; not approved by any regulator, US filing for CagriSema combination submitted Dec 2025 |
What it is
Cagrilintide is a synthetic analogue of human amylin, the hormone pancreatic beta cells release alongside insulin. It is a 37 amino acid peptide with six substitutions against the native sequence and a C20 dicarboxylic acid on the first residue, joined by a gamma-glutamate linker, injected subcutaneously once weekly. Novo Nordisk developed it as AM833 and NNC0174-0833. It is not approved anywhere.
Cagrilintide alone is not CagriSema, and this entry hangs on the distinction. CagriSema is a fixed-dose combination of cagrilintide and semaglutide in one dual-chamber pen. In REDEFINE 1, the same trial over the same 68 weeks at the same 2.4 mg dose, cagrilintide monotherapy gave 11.8 percent weight loss against 2.3 percent on placebo while the combination gave 22.7 percent (Garvey 2025 in the New England Journal of Medicine, with the four-arm breakdown from the sponsor announcement of 20 December 2024). Pages that hand the combination figure to cagrilintide are off by roughly a factor of two.
Figures in this table summarize amounts studied in registered clinical trials. No cagrilintide dose has been established as safe or effective for any use, because the compound is not approved anywhere. This site does not reproduce circulating dosage figures for unregulated cagrilintide. Sold research-use-only material carries no assurance of content or purity, and no clinical protocol exists for the doses and schedules seen circulating (including a widely copied 3x/week, 8-weeks-on/8-weeks-off schedule that has never been tested in any trial).
| Trial / use | Route | Amount studied | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|
| Phase 2 dose-finding, monotherapy (Lau 2021) | Subcutaneous | 0.3, 0.6, 1.2, 2.4 or 4.5 mg | Weekly | 26 weeks (up to 6 wks escalation) | Published human phase 2 clinical trial (Lancet) |
| REDEFINE 1, monotherapy arm (obesity) | Subcutaneous | 2.4 mg | Weekly | 68 weeks | Published human phase 3 clinical trial (NEJM), which gave 11.8% weight loss vs 22.7% for the CagriSema combination |
| REIMAGINE 2, monotherapy arm (type 2 diabetes) | Subcutaneous | 2.4 mg | Weekly | 68 weeks | Published human phase 3 clinical trial (Lancet Diabetes & Endocrinology) |
| RENEW 1 (dedicated monotherapy programme) | Subcutaneous | Dose not disclosed in registry record | Weekly | To week 64 | Registered but unpublished human trial (started Nov 2025) |
| General use, as commonly circulated online | Subcutaneous | Not reproduced here | Some sources report 3x/week schedules, which were never studied in any trial | Not reported | Community / vendor reported: not reproduced for safety reasons; the 5-step titration ladder attributed to this drug is actually the semaglutide ladder relabeled |
How it works
Amylin has no receptor gene of its own. The amylin receptors are heterodimers of the calcitonin receptor, a class B G-protein-coupled receptor encoded by CALCR, paired with one of three receptor activity-modifying proteins to give AMY1, AMY2 and AMY3, which swings preference from calcitonin towards amylin. Cagrilintide is deliberately non-selective across both. Fletcher and colleagues, profiling it in 2021 across 25 endpoints, recorded the observation behind that choice: amylin agonists that also hit the calcitonin receptor appear more efficacious in obesity, even though, in their words, selective activation of calcitonin receptors is not efficacious. Cryo-electron microscopy in 2025 traced the dual activation to the Glu14 to Arg17 salt bridge and the Pro37 contact with the receptor extracellular domain.
The site of action is the hindbrain, not primarily the hypothalamus: the area postrema and the adjacent nucleus of the solitary tract, outside the blood-brain barrier. A 2026 cross-species atlas in Nature Metabolism found that the acute response, in area postrema Calcr and Ramp3 neurons, does not sustain weight loss, while long-term treatment raises prolactin-releasing hormone expression in nucleus of the solitary tract Calcr and Prlh cells. Knocking down dorsal vagal complex Prlh abrogated the effects of cagrilintide but not semaglutide. That is a rat experiment, and it is the cleanest evidence that the two mechanisms are genuinely separate.
Native amylin could not be made into a drug at all. It aggregates into amyloid fibrils, the process that deposits islet amyloid in type 2 diabetes, and it clears in minutes, the obstacle Kruse and colleagues open their 2021 design paper on. Three of cagrilintide’s substitutions are anti-aggregation prolines borrowed from rat amylin, the same three that define pramlintide. The C20 diacid gives reversible albumin binding and a half-life of 159 to 195 hours, 6.6 to 8.1 days (Enebo 2021).
Potential benefits and research applications
Weight loss as a standalone drug
What is being investigated: whether an amylin analogue can produce clinically meaningful weight loss on its own, without a GLP-1 partner. How the effect might occur: dual activation of amylin and calcitonin receptors in the hindbrain, reducing food intake through a satiation pathway distinct from GLP-1 signaling. Evidence: REDEFINE 1, a 3,417-person phase 3 trial, gave 11.8 percent weight loss on the treatment policy estimand against 2.3 percent on placebo, as a single drug. Strength: has been shown in a large, well-controlled human trial. Limitation: it is roughly half the effect size of the combination product tested in the same study, and cagrilintide monotherapy has never been filed for approval anywhere.
Glycemic control in type 2 diabetes
What is being investigated: HbA1c reduction as a standalone agent and combined with semaglutide. How the effect might occur: the same receptor mechanism, applied to glucose-related satiety and intake rather than weight alone. Evidence: the phase 2 Frias 2023 trial found cagrilintide alone lowered HbA1c by 0.9 percentage points against 1.8 for semaglutide, and REIMAGINE 2, the largest monotherapy diabetes dataset at 152 people, found a statistically significant but clinically marginal difference from semaglutide. Strength: has been shown to lower HbA1c in controlled trials; is less effective than semaglutide alone on this measure. Limitation: cagrilintide is not being pursued as a diabetes monotherapy commercially.
Tolerability, the actual thesis behind developing it alone
What is being investigated: whether cagrilintide alone is easier to stay on than GLP-1-based combinations, for people who cannot tolerate them. How the effect might occur: amylin receptor agonism produces a different, generally milder gastrointestinal side-effect profile than GLP-1 agonism. Evidence: in REDEFINE 1, 82.5 percent of cagrilintide monotherapy patients were still on the highest dose at week 68, against 57.3 percent on the combination. A dedicated trial, NCT07607587, is testing it specifically in people who stopped a GLP-1 drug due to gastrointestinal side effects. Strength: is being investigated in a registered human trial designed around this exact question; has not yet reported. Limitation: tolerability is the stated rationale for developing cagrilintide as its own drug, not superior weight-loss potency, which the record does not support.
What the human trials found
The dose-finding trial is Lau 2021 in the Lancet, NCT03856047: 906 adults with overweight or obesity, no diabetes, 26 weeks including up to six weeks of escalation, randomised to cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, liraglutide 3.0 mg daily or placebo. On the trial product estimand weight fell 6.0 to 10.8 percent across the cagrilintide doses against 3.0 percent on placebo, and 4.5 mg beat liraglutide at 10.8 against 9.0 percent. The per-arm estimates for 0.3, 0.6, 1.2 and 2.4 mg are not in the public abstract, so only the range and those anchors appear here.
The 15.4 to 17.1 percent figures often quoted come from the phase 1b trial, Enebo 2021, where all 95 exposed participants received semaglutide 2.4 mg, placebo groups included; they are exploratory combination results. In the phase 2 diabetes trial, Frias 2023, 92 patients, cagrilintide alone lowered HbA1c 0.9 percentage points against 1.8 for semaglutide, and the combination was not superior to semaglutide at p equals 0.075.
REDEFINE 1 randomised 3417 adults for 68 weeks and met both coprimary endpoints: minus 20.4 against minus 3.0 percent on the treatment policy estimand, difference minus 17.3 percentage points, 95 percent confidence interval minus 18.1 to minus 16.6, P less than 0.001. Its four arms on the trial product estimand were 22.7 percent combination, 16.1 semaglutide, 11.8 cagrilintide and 2.3 placebo, and 31.6 percent of the monotherapy group reached 15 percent or more weight loss against 4.7 on placebo. REDEFINE 2, the other filing trial, gave minus 13.7 against minus 3.4 percent in 1206 patients with type 2 diabetes.
The REIMAGINE programme published on 7 June 2026. REIMAGINE 2, 2713 patients, holds the largest cagrilintide monotherapy arm in type 2 diabetes, 152 people. Its primary comparison against semaglutide 2.4 mg on HbA1c gave minus 1.91 against minus 1.75 percentage points, a difference of minus 0.16 percentage points, confidence interval minus 0.27 to minus 0.05, p equals 0.0035: significant in 1208 patients, clinically marginal, and reported as a win without being shown at that size. REIMAGINE 3 added the combination to basal insulin in 274 patients and reported, verbatim, that no severe hypoglycaemia was reported.
REDEFINE 4, NCT06131437, is the only head-to-head the molecule has been in: 809 people with obesity, 84 weeks, against tirzepatide 15 mg. On 23 February 2026 the sponsor announced 23.0 against 25.5 percent on the efficacy estimand and 20.2 against 23.6 on the treatment regimen estimand, stating verbatim that CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks. There is no publication and no disclosed confidence intervals. Failing non-inferiority is not being ineffective, but the claim that this is the most effective obesity treatment available is not supported by the only head-to-head that exists.
The REDEFINE 1 expectation gap, and the arithmetic
Novo Nordisk had guided to roughly 25 percent. REDEFINE 1 read out at 22.7 on the trial product estimand and 20.4 on treatment policy, the share price fell about a fifth in a session and the trial has been called a failure ever since. It met every prespecified endpoint. The sponsor’s own explanation is the strongest: dosing was flexible, and at week 68 only 57.3 percent of combination recipients were still on the highest dose, against 82.5 percent on cagrilintide monotherapy and 70.2 on semaglutide.
The same arithmetic settles the word synergy. On that estimand semaglutide gave 13.8 percentage points of effect over placebo and cagrilintide gave 9.5, summing to 23.3. The combination gave 20.4. Additive at best, arguably sub-additive, and nothing in it is synergistic.
A standalone drug again, which is new
Until late 2025 cagrilintide appeared alone only as a comparator arm. On 16 September 2025 the sponsor presented the REDEFINE 1 monotherapy data and announced a dedicated phase 3 programme, RENEW. RENEW 1, NCT07220642, randomised 300 adults without diabetes against placebo to a week 64 endpoint, and a companion diabetes trial, NCT07220759, enrolled 330, both from November 2025. The thesis is tolerability, not potency, and the 82.5 against 57.3 percent dose retention is the argument. NCT07607587 states it out loud, testing tolerability in 114 people who stopped GLP-1 receptor agonists because of gastrointestinal side effects.
Safety, with the denominators
Gastrointestinal events are the class effect, mostly mild to moderate and transient. In the dose-finding trial they affected 41 to 63 percent across cagrilintide doses against 32 on placebo. In REDEFINE 1 the combination produced them in 79.6 percent against 39.9, with nausea 55 and vomiting 26.1. In REIMAGINE 2 the monotherapy arm had any adverse event in 82.2 percent, 125 of 152, between placebo at 70.5 and semaglutide at 81.2. Rates for the same regimen vary widely between trials.
Three findings rarely seen elsewhere. A 2026 meta-analysis of three randomised trials put administration-site conditions at a relative risk of 3.27 against semaglutide, 95 percent confidence interval 1.27 to 8.46, and serious adverse events on cagrilintide monotherapy at 1.83, interval 1.03 to 3.24, weak because it barely excludes 1.0 but the only such comparison there is. The cagrilintide plus semaglutide arm of the MASH trial NCT05016882 was not substantially different from placebo on fibrosis while semaglutide alone was nominally significant, a negative result. And the 2026 BMJ network meta-analysis of 262 trials and 99,791 participants placed the combination among the agents with the highest discontinuation for adverse events, with a fatigue relative risk of 3.2, about 92 more cases per 1000 in a year.
Hypoglycaemia is not an intrinsic risk: amylin receptor agonism is not insulinotropic, and pramlintide’s hypoglycaemia came from the mealtime insulin beside it. No amylin receptor agonist has completed a cardiovascular outcomes trial.
Cagrilintide was given with semaglutide at two lower doses in the phase 3 REDEFINE 9 trial, reported by the manufacturer on 14 November 2026. The REDEFINE 9 analysis explains why similar averages for the two doses do not show they work equally well.
Bone: new company-reported data, 16 November 2026
Novo Nordisk reported new bone findings at ObesityWeek in a 16 November 2026 release. In an eight-week study in ovariectomized rats, a model of postmenopausal bone loss, femoral trabecular bone volume was 43% higher with cagrilintide and 40% higher with CagriSema than in weight-matched controls, and both differences were statistically significant. Zenagamtide (30% higher) and semaglutide (11% higher) were not significantly different. In small studies in healthy volunteers, cagrilintide suppressed CTX-I, a blood marker of bone breakdown, while the selective amylin receptor agonist NN1213 did not. In the 252-person bone density substudy of REDEFINE 1, bone mineral density fell with CagriSema over 68 weeks, as expected with large weight loss, but stayed within the normal range for age and sex.
These are company-reported figures from rats, blood markers and a bone density substudy. They are not fracture outcomes, and whether cagrilintide protects bone in people has not been shown.
Regulatory status
A new drug application for the combination went to the US FDA on 18 December 2025, on REDEFINE 1 and 2. It is not approved. No action date has been made public, no approval in any jurisdiction, and the sponsor says only that the FDA is expected to review it in 2026. No European application has been publicly confirmed, so European status is unknown rather than filed. REDEFINE 4 was not part of the filing basis. Cagrilintide monotherapy is filed nowhere.
A dated list of what is expected next for cagrilintide, with the source for each date, is on its card on the Weight Loss Atlas pipeline tracker.
What circulates, and why no numbers appear here
Cagrilintide circulates as lyophilised powder under research-use framing, alongside written protocols that read like prescriptions. This site does not reproduce those figures, because the compound is unapproved for every use, because the escalation is where the harm sits, and because nothing in that supply chain establishes that a vial holds what its label claims.
What the record does show is this. One widely copied page carries a dose given three days a week and an eight weeks on, eight weeks off cycle. Every human cagrilintide trial since first-in-human in 2014 has dosed once weekly, which is what a half-life of 159 to 195 hours dictates, and three injections a week of a peptide with a one week half-life would accumulate towards roughly triple the studied exposure. No trial has tested that frequency or any cycling schedule. A second item is a five-step titration ladder attributed to Lau 2021: it is the semaglutide ladder with cagrilintide’s name on it, and its lowest step has never been given as a cagrilintide dose in any published trial.
The rest of the amylin field
Calling cagrilintide the amylin was defensible in 2022. A 2026 review lists cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295 and AZD6234 in human development, plus zenagamtide, the compound formerly called amycretin, a rename that breaks older cross-links. Eloralintide, a selective agonist, reached roughly 20 percent weight loss at 48 weeks as a single drug in Billings 2025, against cagrilintide’s 11.8 at 68 weeks, and petrelintide had 98 percent of its phase 2 participants reach the maintenance dose.
What the record gets wrong
That the lipid is a C18 fatty acid. It is eicosanedioic acid, a C20 alpha,omega-dicarboxylic acid, on Lys1 through a gamma-glutamate linker. That is not cosmetic: a diacid presents a free terminal carboxylate that changes the albumin-binding geometry. Semaglutide uses a C18 diacid, so the claim reads as semaglutide chemistry stapled onto cagrilintide.
That CagriSema failed REDEFINE 1, when it met every prespecified endpoint and missed a commercial guidance figure, which are different events. That it is the amylin, when six others are in development and two already beat it on the measures above.
The accurate sentence about cagrilintide in September 2026 is a narrow one. It is an investigational once-weekly amylin analogue that produced 11.8 percent weight loss over 68 weeks as a single drug, it is the most clinically advanced amylin programme and neither the most potent nor the best tolerated, it is approved nowhere for anything, and almost every number larger than 12 percent attached to its name belongs to two drugs rather than to this one.
Pfizer has registered an early-phase study of its amylin analog MET-233i given together with berobenatide (MET-097i), its once-monthly GLP-1 candidate. The berobenatide entry lists that study and the Phase 3 program.
Frequently asked questions
What is cagrilintide?
An investigational, once-weekly injectable analogue of amylin, developed by Novo Nordisk both as a standalone drug and combined with semaglutide as CagriSema. It is not approved anywhere.
How does it work?
It activates amylin and calcitonin receptors together in the hindbrain, reducing food intake through a satiation pathway distinct from GLP-1 drugs. It was engineered with anti-aggregation substitutions and a fatty-acid attachment for a once-weekly half-life of roughly 6.6 to 8.1 days.
What dosage has been studied?
Doses from 0.16 mg up to 4.5 mg once weekly across trials, but every phase 3 trial since 2021 has used 2.4 mg once weekly, self-injected, after an escalation period of up to six weeks.
Is cagrilintide the same as CagriSema?
No. CagriSema is cagrilintide combined with semaglutide. In the same 68-week trial, cagrilintide alone produced 11.8 percent weight loss and the combination produced 22.7 percent. Figures above roughly 15 percent belong to the combination, not to cagrilintide by itself.
What dosage commonly circulates online?
This site does not reproduce circulating dosage figures for cagrilintide. It is unapproved for every use, sold research-use-only material carries no assurance of content or purity, and no clinical protocol exists for the doses and schedules seen circulating.
Has it been studied in humans?
Extensively, in a large phase 3 programme (REDEFINE) spanning weight management and type 2 diabetes, plus a dedicated monotherapy programme (RENEW) that started enrolling in November 2025.
How does it compare to tirzepatide?
The only head-to-head trial, REDEFINE 4, compared the CagriSema combination (not cagrilintide alone) to tirzepatide 15 mg and announced in February 2026 that it did not meet non-inferiority on weight loss. No published data or confidence intervals are available yet.
What side effects have been reported?
Mostly mild to moderate gastrointestinal effects, occurring at somewhat higher rates on cagrilintide-containing regimens than on semaglutide alone in some analyses, plus a higher rate of injection-site reactions. No amylin receptor agonist has completed a cardiovascular outcomes trial.
Is it approved anywhere?
No. A US new drug application for the CagriSema combination was submitted in December 2025 based on the REDEFINE trials, with a decision expected sometime in 2026. Cagrilintide alone is filed nowhere.
What remains unknown?
Arm-level monotherapy data in type 2 diabetes, fracture and long-term bone outcomes given chronic calcitonin receptor engagement (only preliminary bone findings exist so far, summarized under Safety), whether appetite suppression involves aversive as well as satiating effects, cardiovascular outcomes, and what happens to weight after stopping.
Bottom line
Cagrilintide is a real, well-studied amylin analogue with a genuine standalone effect: 11.8 percent weight loss over 68 weeks in its largest trial, roughly half of what its combination with semaglutide produces in the same study. Its own phase 3 programme, RENEW, is being argued on tolerability rather than superior potency, since monotherapy patients stayed on their highest dose far more often than combination patients did. It has real utility, mostly for glycemic control and as a gentler alternative for people who cannot tolerate GLP-1 drugs, but it is not approved for anything, has no completed cardiovascular outcomes data, and much of the impressive weight-loss figures attached to its name in casual conversation actually belong to CagriSema.
Every amount studied in the phase 2 and phase 3 trials, and the online figures no trial supports, are in the cagrilintide dosage guide.
Sources
- Nielsen MJF, Becker NP, Duus HHH, Kirkeby K, Kupcova V, Lauenborg BW, Low B, Svolgaard O, Witten L. Renal or hepatic impairment does not affect pharmacokinetics, safety, or tolerability of subcutaneous cagrilintide. Clin Pharmacokinet. 2026. Human phase 1, two single dose studies registered as NCT04209049 and NCT05564104. Source for the single 0.6 mg dose given to 33 participants in the renal impairment study and the single 0.9 mg dose given to 32 participants in the hepatic impairment study, each stratified into normal function and mild, moderate and severe impairment. PMID 42228334
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet 2021;398(10317):2160-2172. NCT03856047. Human, n=906, 26 weeks. Establishes 6.0 to 10.8 percent weight loss across 0.3 to 4.5 mg against 3.0 percent placebo, the six week escalation period, and gastrointestinal events in 41 to 63 percent. PMID 34798060
- Enebo LB, Berthelsen KK, Kankam M, et al. Concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg: a randomised, controlled, phase 1b trial. Lancet 2021;397(10286):1736-1748. NCT03600480. Human, n=95 exposed, 20 weeks. The source of the human half-life of 159 to 195 hours, of dose-proportional exposure and of the exploratory combination weight-loss figures. PMID 33894838
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: phase 2 trial. Lancet 2023;402(10403):720-730. NCT04982575. Human, n=92, 32 weeks. Cagrilintide alone lowered HbA1c 0.9 points against 1.8 for semaglutide, and the combination was not superior to semaglutide on HbA1c (p=0.075). PMID 37364590
- Garvey WT, Bluher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025;393(7):635-647. NCT05567796. Human, n=3417, 68 weeks. Minus 20.4 against minus 3.0 percent placebo on the treatment policy estimand; contains the cagrilintide 2.4 mg monotherapy arm of 302 people. PMID 40544433
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med 2025;393(7):648-659. NCT05394519. Human, n=1206, 68 weeks. Minus 13.7 against minus 3.4 percent placebo. No active comparator and no monotherapy arm. PMID 40544432
- Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol 2026;14(8):662-677. NCT06065540. Human, n=2713, 68 weeks. HbA1c difference against semaglutide 2.4 mg of minus 0.16 percentage points (95% CI minus 0.27 to minus 0.05, p=0.0035); holds the largest cagrilintide monotherapy arm in diabetes, n=152. PMID 42251859
- Cagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): phase 3. Lancet 2026. NCT06323161. Human, n=274, 40 weeks. HbA1c minus 2.33 and minus 2.10 against minus 0.66 percentage points placebo, and the statement that no severe hypoglycaemia was reported. PMID 42251856
- Loomba R, George J, Castera L, et al. Zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to MASH: phase 2. Lancet Gastroenterol Hepatol 2026;11(9):797-811. NCT05016882. Human. The exploratory cagrilintide 2.4 mg plus semaglutide 2.4 mg arm of 99 people was not substantially different from placebo on fibrosis improvement, while semaglutide alone was nominally significant. PMID 42456707
- Fletcher MM, Keov P, Truong TT, et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors. J Pharmacol Exp Ther 2021;377(3):417-440. Preclinical. The definitive receptor pharmacology across 25 endpoints, establishing cagrilintide as a non-selective amylin and calcitonin receptor agonist and that calcitonin receptor selective activation alone is not efficacious. PMID 33727283
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 2021;64(15):11183-11194. Preclinical. The primary design account: the amyloid obstacle, the anti-aggregation substitutions and the selection of cagrilintide for clinical development. PMID 34288673
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacol Sin 2025;47(1):162-172. Preclinical. Independently confirms residues Glu14, Arg17, Phe23 and Pro37 and explains the bypass binding mode that permits non-selective activation. PMID 40847076
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. Nat Metab 2026;8(8). Preclinical, rat, mouse and macaque. Nucleus of the solitary tract Calcr and Prlh neurons mediate the durable effect, and knocking down dorsal vagal complex Prlh abrogates cagrilintide but not semaglutide in rats. PMID 42260119
- Efficacy and safety of cagrilintide and CagriSema versus semaglutide as anti-obesity medications: systematic review, meta-analysis and meta-regression. Diabetes Obes Metab 2026;28(6):4828-4836. Human, 3 randomised trials, n=3545. Administration-site conditions relative risk 3.27 (95% CI 1.27 to 8.46) and cagrilintide monotherapy serious adverse events relative risk 1.83 (1.03 to 3.24) against semaglutide. PMID 41834765
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ 2026. Human, 262 trials, n=99,791. Places CagriSema among the agents with the highest discontinuation for adverse events and reports a fatigue relative risk of 3.2, about 92 more events per 1000 in a year. PMID 42419792
- Alhazmi A, et al. Amylin analogs: the next major class of weight loss therapy. Diabetes Obes Metab 2026, current to 30 April 2026. Narrative review. The competitive inventory: cagrilintide, eloralintide, petrelintide, MET-233i, ABBV-295 and AZD6234, plus combination approaches including CagriSema and zenagamtide. PMID 42452898
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist: a 48-week phase 2 trial. Lancet 2025;406(10520):2631-2643. NCT06230523. Human, n=263. Weight change of minus 9 to minus 20 percent across 1 to 9 mg against minus 0.4 percent placebo, with nausea reaching 64 percent at 6 mg and fatigue 46 percent at 6 to 9 mg. PMID 41207310
- Novo Nordisk. Phase 3 trial of cagrilintide monotherapy against placebo in adults with obesity or overweight without diabetes, n=300, randomised 2 to 1, primary endpoint relative weight change at week 64. Started November 2025, no results posted. Excludes anyone previously dosed with an amylin-based compound. NCT07220642
- Novo Nordisk company announcements of 20 December 2024 (REDEFINE 1 four-arm breakdown on both estimands and dose retention of 57.3, 82.5 and 70.2 percent), 16 September 2025 (cagrilintide monotherapy data and the RENEW programme), 18 December 2025 (CagriSema new drug application submitted on REDEFINE 1 and 2) and 23 February 2026 (REDEFINE 4 topline, non-inferiority against tirzepatide 15 mg not met), together with the Roche and Zealand Pharma announcement of 5 March 2026 on petrelintide phase 2. Human trials reported by sponsors without peer-reviewed publication. Company announcements, 20 December 2024 to 23 February 2026
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
Compare Cagrilintide with related compounds
Research area: Metabolic and incretin.